Stocksigma LogoStocksigma Logo

Venmax Drugs Schedules Board Meeting to Approve Q2 Results

Venmax Drugs and Pharmaceuticals announced that its Board of Directors will meet on 12th Nov'26 to consider and approve the unaudited standalone financial

Venmax Drugs Schedules Board Meeting to Approve Q2 Results

Venmax Drugs and Pharmaceuticals Ltd 路 Intimation 路 12 Nov 2026, 5:30 am

Venmax Drugs Schedules Board Meeting to Approve Q2 Results Venmax Drugs and Pharmaceuticals announced that its Board of Directors will meet on 12th Nov'26 to consider and approve the unaudited standalone financial results for the quarter ended 30th Sep'26. Additionally, the trading window for dealing in company securities, which closed on 1st Oct'26 for designated persons, will remain shut until 14th Nov'26 (48 hours post-financial results approval).

Original exchange filing (PDF)

More announcements from Venmax Drugs and Pharmaceuticals Ltd

All Venmax Drugs and Pharmaceuticals Ltd announcements